Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: Their treatment in adolescents

Annals of the New York Academy of Sciences

Volumn 1135, Issue , 2008, Pages 219-229

  Joffe, Hadine ^a,b   Hayes, Frances J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bipolar disorder; Epilepsy; Hypothalamic pituitary gonadal (HPG) axis; Menstrual cycle dysfunction; Migraines; Polycystic ovarian syndrome (PCOS); Valproate

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; GONADORELIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LUTEINIZING HORMONE; OLANZAPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROLACTIN; QUETIAPINE; RISPERIDONE; TESTOSTERONE; THIORIDAZINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; BONE DENSITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FOLLITROPIN BLOOD LEVEL; GALACTORRHEA; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MENTAL DISEASE; MIGRAINE; NEUROLOGIC DISEASE; OLIGOMENORRHEA; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PROLACTIN BLOOD LEVEL; SIDE EFFECT;

EID: 45549084568     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1429.030     Document Type: Conference Paper

References (91)

1. Hauser, W.A., J.F. Annegers & L.T. Kurland. 1993. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34 : 453 468.
2. Hauser, W.A., J.F. Annegers & L.T. Kurland. 1991. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 32 : 429 445.
3. Tharp, B.R. 1998. Epilepsy in infants and children. In Conn's Current Therapy. R.E. Rakel, Ed. : 883. W. B. Saunders Co. Philadelphia, PA.
4. Lewinsohn, P.M., D.N. Klein & J.R. Seeley. 2000. Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord. 2 : 281 293.
5. Merikangas, K.R., H.S. Akiskal, J. Angst, et al. 2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 64 : 543 552.
6. Suppes, T., E.B. Dennehy & E.W. Gibbons. 2000. The longitudinal course of bipolar disorder. J. Clin. Psychiatry 61 (Suppl 9 23 30.
7. Baldassano, C.F., L. Marangell, S. Nassir Ghaemi, et al. 2005. Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar. Disord. 7(5): 465-470.
8. Moreno, C., G. Laje, C. Blanco, et al. 2007. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry 64 : 1032 1039.
9. Dalsgaard-Nielsen, T. 1970. Some aspects of the epidemiology of migraine in Denmark. Headache 10 : 14 23.
10. Sillanpaa, M. 1983. Changes in the prevalence of migraine and other headaches during the first seven school years. Headache 23 : 15 19.
11. Vahlquist, B. 1955. Migraine in children. Int. Arch. Allergy Appl. Immunol. 7 : 348 355.
12. Zwart, J.A., G. Dyb, T.L. Holmen, et al. 2004. The prevalence of migraine and tension-type headaches among adolescents in Norway. The Nord-Trondelag Health Study (Head-HUNT-Youth), a large population-based epidemiological study. Cephalalgia 24 : 373 379.
13. Bilo, L., R. Meo, R. Valentino, et al. 1991. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil. Steril. 55 : 705 711.
14. Herzog, A.G., M.M. Seibel, D.L. Schomer, et al. 1986. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch. Neurol. 43 : 341 346.
15. Nappi, C., R. Meo, C. Di Carlo, et al. 1994. Reduced fertility and neuroendocrine dysfunction in women with epilepsy. Gynecol. Endocrinol. 8 : 133 145.
16. Bilo, L. & R. Meo. 2006. Epilepsy and polycystic ovary syndrome: where is the link? Neurol. Sci. 27 : 221 230.
17. Klein, P., A. Serje & J.C. Pezzullo. 2001. Premature ovarian failure in women with epilepsy. Epilepsia 42 : 1584 1589.
18. Bilo, L., R. Meo, R. Valentino, et al. 2001. Characterization of the reproductive endocrine disorders in women with epilepsy. J. Clin. Endocrinol. Metab. 86 : 2950 2956.
19. Isojarvi, J.I., T.J. Laatikainen, A.J. Pakarinen, et al. 1993. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329 : 1383 1388.
20. Luef, G., I. Abraham, M. Haslinger, et al. 2002. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J. Neurol. 249 : 835 841.
21. Murialdo, G., C.A. Galimberti, F. Magri, et al. 1997. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J. Endocrinol. Invest. 20 : 519 526.
22. Morrell, M.J., F.J. Hayes, P.M. Sluss, et al. 2008. Hyperandrogenism, ovulatory dysfunction, and PCOS with valproate vs lamotrigine. Ann. Neurol. In press
23. Murphy, M.K., J.E. Hall, J.M. Adams, et al. 2006. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 : 3878 3884.
24. Mikkonen, K., L.K. Vainionpaa, A.J. Pakarinen, et al. 2004. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 62 : 445 450.
25. Herzog, A.G. 1993. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 43 : 1907 1910.
26. Bilo, L., R. Meo, C. Nappi, et al. 1988. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 29 : 612 619.
27. Lofgren, E., K. Mikkonen, U. Tolonen, et al. 2007. Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication. Epilepsy Behav. 10 : 77 83.
28. Joffe, H., D.R. Kim, J.M. Foris, et al. 2006. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. J. Clin. Psychiatry 67 : 297 304.
29. Joffe, H., L.S. Cohen, T. Suppes, et al. 2006. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry 59(11): 1078-1086.
30. Betts, T., H. Yarrow, N. Dutton, et al. 2003. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 12 : 323 329.
31. Morrell, M.J., L. Giudice, K.L. Flynn, et al. 2002. Predictors of ovulatory failure in women with epilepsy. Ann. Neurol. 52 : 704 711.
32. Morrell, M.J., J. Isojarvi, A.E. Taylor, et al. 2003. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res. 54 : 189 199.
33. Prabhakar, S., P. Sahota, P.S. Kharbanda, et al. 2007. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 48 : 1371 1377.
34. Bauer, J., A. Jarre, D. Klingmuller & C.E. Elger. 2000. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 41 : 163 167.
35. Isojarvi, J.I., J. Rattya, V.V. Myllyla, et al. 1998. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43 : 446 451.
36. Joffe, H., A.E. Taylor & J.E. Hall. 2001. Polycystic ovarian syndrome - relationship to epilepsy and antiepileptic drug therapy. J. Clin. Endocrinol. Metab. 86 : 2946 2949.
37. Joffe, H., J.E. Hall, A.E. Taylor, et al. 2003. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorder. Harv. Rev. Psychiatry. 11(2): 99-108.
38. Rasgon, N.L., L.L. Altshuler, L. Fairbanks, et al. 2005. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord. 7 : 246 259.
39. Joffe, H., L.S. Cohen, T. Suppes, et al. 2006. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol. Psychiatry 60 : 1378 1381.
40. de Vries, L., A. Karasik, Z. Landau, et al. 2007. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 48 : 470 477.
41. El-Khayat, H.A., F.Z. Abd El-Basset, H.Y. Tomoum, et al. 2004. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 45 : 1106 1115.
42. Rattya, J., J. Turkka, A.J. Pakarinen, et al. 2001. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 56 : 31 36.
43. Vainionpaa, L.K., J. Rattya, M. Knip, et al. 1999. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann. Neurol. 45 : 444 450.
44. Rattya, J., L. Vainionpaa, M. Knip, et al. 1999. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 103 : 588 593.
45. Lemarchand-Beraud, T., M.M. Zufferey, M. Reymond & I. Rey. 1982. Maturation of the hypothalamo-pituitary-ovarian axis in adolescent girls. J. Clin. Endocrinol. Metab. 54 : 241 246.
46. Lundberg, B., A. Nergardh, E.M. Ritzen & K. Samuelsson. 1986. Influence of valproic acid on the gonadotropin-releasing hormone test in puberty. Acta Paediatr. Scand. 75 : 787 792.
47. Cook, J.S., J.F. Bale & R.P. Hoffman. 1992. Pubertal arrest associated with valproic acid therapy. Pediatr. Neurol. 8 : 229 231.
48. Laforet, G.A., G. Apostol, W.Z. Robieson, et al. 2007. Reproductive endocrine effects of divalproex sodium extended-release in adolescent females. In Child Neurology Society, 36th Annual Meeting : Quebec City, Canada.
49. Nelson-DeGrave, V.L., J.K. Wickenheisser, J.E. Cockrell, et al. 2004. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 145 : 799 808.
50. Wood, J.R., V.L. Nelson-Degrave, E. Jansen, et al. 2005. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol. Genom. 20 : 233 243.
51. Fluck, C.E., D.C. Yaworsky & W.L. Miller. 2005. Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia 46 : 444 448.
52. Herzog, A.G. 1996. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann. Neurol. 39 : 559 560.
53. Misra, M., G.I. Papakostas & A. Klibanski. 2004. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry 65 : 1607 1618 quiz :590, 760-761.
54. Joffe, H. 2007. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. J. Clin. Psychiatry 68 (Suppl 9 10 15.
55. Crawford, A.M., C.M. Beasley & G.D. Tollefson. 1997. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 26 : 41 54.
56. Tollefson, G.D., C.M. Beasley, P.V. Tran, et al. 1997. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154 : 457 465.
57. Tran, P.V., S.H. Hamilton & A.J. Kuntz, et al. 1997. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 : 407 418.
58. Svestka, J., O. Synek, J. Tomanova, et al. 2007. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol. Lett. 28 : 881 818.
59. Correll, C.U. & H.E. Carlson. 2006. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 45 : 771 791.
60. Kinon, B.J., J.A. Gilmore, H. Liu & U.M. Halbreich. 2003. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28 (Suppl 2 69 82.
61. Kinon, B.J., J.A. Gilmore, H. Liu & U.M. Halbreich. 2003. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (Suppl 2 55 68.
62. Findling, R.L., V. Kusumakar, D. Daneman, et al. 2003. Prolactin levels during long-term risperidone treatment in children and adolescents. J. Clin. Psychiatry 64 : 1362 1369.
63. Nordstrom, A.L. & L. Farde. 1998. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J. Clin. Psychopharmacol. 18 : 305 310.
64. Meltzer, H.Y. & V.S. Fang. 1976. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch. Gen. Psychiatry 33 : 279 286.
65. Smith, S., M.J. Wheeler, R. Murray & V. O'Keane. 2002. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J. Clin. Psychopharmacol. 22 : 109 114.
66. Richelson, E. & T. Souder. 2000. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68 : 29 39.
67. Becker, D., O. Liver, R. Mester, et al. 2003. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J. Clin. Psychiatry 64 : 761 766.
68. Henderson, D.C., D.C. Goff, C.E. Connolly, et al. 2001. Risperidone added to clozapine: impact on serum prolactin levels. J. Clin. Psychiatry 62 : 605 608.
69. Kearns, A.E., D.C. Goff, D.L. Hayden & G.H. Daniels. 2000. Risperidone-associated hyperprolactinemia. Endocr. Pract. 6 : 425 429.
70. Turrone, P., S. Kapur, M.V. Seeman & A.J. Flint. 2002. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry 159 : 133 135.
71. Volavka, J., P. Czobor, T.B. Cooper, et al. 2004. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychiatry 65 : 57 61.
72. Kleinberg, D.L., J.M. Davis & R. de Coster, et al. 1999. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19 : 57 61.
73. Magharious, W., D.C. Goff & E. Amico. 1998. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 77 : 159 166.
74. Polishuk, W.Z. & S. Kulcsar. 1956. Effects of chlorpromazine on pituitary function. J. Clin. Endocrinol. Metab. 16 : 292 293.
75. Smith, S.M., V. O'Keane & R. Murray. 2002. Sexual dysfunction in patients taking conventional antipsychotic medication. Br. J. Psychiatry 181 : 49 55.
76. Ghadirian, A.M., G. Chouinard & L. Annable. 1982. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 170 : 463 467.
77. Windgassen, K., U. Wesselmann & H. Schulze Monking. 1996. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology 33 : 142 146.
78. Bobes, J., A.P.M.P. Garc, J. Rejas, et al. 2003. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J. Sex. Marital. Ther. 29 : 125 147.
79. Kim, K.S., C.U. Pae, J.H. Chae, et al. 2002. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J. Clin. Psychiatry 63 : 408 413.
80. Keller, R. & F. Mongini. 2002. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol. Sci. 23 : 233 235.
81. Takahashi, H., H. Higuchi, M. Kamata, et al. 2003. Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J. Neuropsychiatry Clin. Neurosci. 15 : 375 377.
82. Lee, B.H., Y.K. Kim & S.H. Park. 2006. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 : 714 717.
83. Weiden, P.J., D.G. Daniel, G. Simpson & S.J. Romano. 2003. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Clin. Psychopharmacol. 23 : 595 600.
84. Shim, J.C., J.G. Shin, D.L. Kelly, et al. 2007. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am. J. Psychiatry 164 : 1404 1410.
85. Ataya, K., A. Mercado, J. Kartaginer, et al. 1988. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil. Steril. 50 : 876 881.
86. Bilici, M., H. Cakirbay, M. Guler, et al. 2002. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int. J. Neurosci. 112 : 817 828.
87. Woods, S.W., A. Martin, S.G. Spector & T.H. McGlashan. 2002. Effects of development on olanzapine-associated adverse events. J. Am. Acad. Child Adolesc. Psychiatry 41 : 1439 1446.
88. Wudarsky, M., R. Nicolson, S.D. Hamburger, et al. 1999. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J. Child Adolesc. Psychopharmacol. 9 : 239 245.
89. Seeman, P., N.H. Bzowej, H.C. Guan, et al. 1987. Human brain dopamine receptors in children and aging adults. Synapse 1 : 399 404.
90. Becker, A.L. & C.N. Epperson. 2006. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Child Adolesc. Psychiatr. Clin. N. Am. 15 : 207 220.
91. Cohen, L.G. & J. Biederman. 2001. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J. Child Adolesc. Psychopharmacol. 11 : 435 440.